Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.55 |
| ▸ | NNMT | P40261 | 2/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213324 | 1.00 | CYP11B2 (0.55) | CYP11B2NNMTPIK3C3CYP11B1MKNK1 | |
| SCHEMBL16196125 | 0.86 | CYP11B2 (0.57) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL16196188 | 0.81 | CYP11B2 (0.57) | CYP11B2NNMTPIK3C3ASIC3 | |
| SCHEMBL16196406 | 0.77 | CYP11B2 (0.53) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL16196089 | 0.77 | NNMT (0.47) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL16196646 | 0.75 | CYP11B2 (0.54) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL16196012 | 0.74 | CYP11B2 (0.55) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL20237379 | 0.74 | CYP11B2 (0.55) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL16196626 | 0.74 | CYP11B2 (0.50) | CYP11B2NNMTPIK3C3CYP11B1ASIC3 | |
| SCHEMBL20245397 | 0.73 | CYP11B2 (0.73) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, REN | CYP11B2 4/4885NNMT 637/4885PIK3C3 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.